3720 Spectrum Blvd., Suite 125, Tampa, FL 33612
An overview of the products being researched, developed, and a brief summary of our pipeline.
Chronic diseases continue to be underserved by the current, prevalent mono-therapeutic approaches (which are partially effective at best), creating persisting unmet medical needs. Our objective is to select for and bring to market, clinically differentiated, superior combination nanomedicines that mitigate unmet medical needs in large therapeutic areas to create maximal patient impact.
* Human PoC – Human Proof-of-Concept Study, Open-label, Non-Randomized
** Pre-IND meeting with USFDA completed, feedback on Phase 3 Clinical Development plan obtained
In a study (published by BMC Ophthalmology) for Dry Eye Disease (DED), MNP Cyclosporine was (1) statistically superior to Restasis beginning 4 weeks of treatment and (2) more tolerable.
Current/Future Step(s):
SGN-624 comprises a transdermal, fixed-dose combination of two active pharmaceutical ingredients targeting inflammatory and neuropathic components of pain.
SGN-624 demonstrated significant efficacy in an open-label, single-center study involving 94 patients with advanced, medically refractory chronic knee osteoarthritis (OA) and spinal pain. At baseline, 97.9% of patients were taking oral NSAIDs and 69.1% were taking opioids.
Treatment: High-dose GM-624 nanolotion applied twice daily for 15 days to 3 months.
In a recently concluded two-center, open-label study involving 19 patients with uncontrolled diabetic neuropathy treated with SGN-516, 15 of the 19 patients experienced a 50–80% improvement from baseline within one month of treatment.
In addition, 4 patients who had experienced loss of tactile sensation in their fingertips (3 patients) or feet (1 patient) recovered sensory perception within 3 months of treatment initiation.